Hudson Bay Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Hudson Bay Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.93M	Buy	+25,860	New	+$1.81M	0.01%	827
2025 Q2	–	Sell	-150,000	Closed	-$5.19M	–	1387
2025 Q1	$5.19M	Buy	150,000 +37,465	+33%	+$1.26M	0.02%	584
2024 Q4	$3.09M	Buy	+112,535	New	+$2.91M	0.01%	583
2024 Q3	–	Sell	-38,946	Closed	-$987K	–	865
2024 Q2	$987K	Buy	+38,946	New	+$1.06M	﹤0.01%	607
2023 Q2	–	Sell	-72,300	Closed	-$1.2M	–	859
2023 Q1	$1.2M	Buy	+72,300	New	+$843K	0.01%	573
2022 Q4	–	Sell	-30,000	Closed	-$298K	–	991
2022 Q3	$298K	Sell	30,000 -70,000	-70%	-$727K	﹤0.01%	911
2022 Q2	$908K	Buy	100,000 +50,000	+100%	+$418K	0.01%	951
2022 Q1	$508K	Buy	+50,000	New	+$513K	0.01%	875
2021 Q4	–	Sell	-20,000	Closed	-$937K	–	1092
2021 Q3	$937K	Buy	+20,000	New	+$1.07M	0.01%	762
2020 Q3	–	Sell	-10,000	Closed	-$326K	–	549
2020 Q2	$326K	Buy	+10,000	New	+$305K	0.01%	424

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Hudson Bay Capital Management's BBIO Position: Q2 2026 in Review

Hudson Bay Capital Management opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 25,860 shares worth $1.93M. The stake represents 0.01% of the portfolio and ranks #827 among its holdings. This is a return to the name: Hudson Bay Capital Management previously reported a position in BBIO as recently as Q1 2025.

Hudson Bay Capital Management first reported a position in BBIO in Q2 2020 and has held it in 10 quarters since. The position peaked at $5.19M in Q1 2025. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Hudson Bay Capital Management held 25,860 shares of BridgeBio Pharma worth $1.93M as of Q2 2026.
BridgeBio Pharma was a new Hudson Bay Capital Management position in Q2 2026.
BridgeBio Pharma made up 0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #827 holding.
Hudson Bay Capital Management first reported a position in BridgeBio Pharma in Q2 2020 and has held it in 10 quarters since.
Hudson Bay Capital Management's BridgeBio Pharma position peaked at $5.19M in Q1 2025.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.